Who
Nicholas Grund
Chief Commercial Officer
Company insider
Files Form 4 as: Chief Commercial Officer, Akebia Therapeutics; Chief Commercial Officer, Amag Pharmaceuticals.
In numbers
- Trades disclosed
- 29
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $353K
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 4 Jan 2016
- Last trade
- 2 Feb 2026
- Last filed
- 4 Feb 2026
Companies traded
Activity over time
1 Feb 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Feb 2026filed 4 Feb 2026 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $74K53,585 at $1.39 | filing |
| 2 Feb 2026filed 4 Feb 2026 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $43K31,244 at $1.39 | filing |
| 2 Feb 2026filed 4 Feb 2026 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $74K53,585 at $1.39 | filing |
| 2 Feb 2026filed 4 Feb 2026 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $43K31,244 at $1.39 | filing |
| 30 Jan 2026filed 3 Feb 2026 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Code A | —204,000 at $0.00 | filing |
| 30 Jan 2026filed 3 Feb 2026 | AKBA Akebia Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —320,000 at $0.00 | filing |
| 30 Jan 2026filed 3 Feb 2026 | AKBA Akebia Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —320,000 at $0.00 | filing |
| 30 Jan 2026filed 3 Feb 2026 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Code A | —204,000 at $0.00 | filing |
| 3 Feb 2025filed 4 Feb 2025 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $117K55,621 at $2.10 | filing |
| 31 Jan 2025filed 4 Feb 2025 | AKBA Akebia Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —292,300 at $0.00 | filing |
| 31 Jan 2025filed 4 Feb 2025 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Code A | —194,900 at $0.00 | filing |
| 31 Jan 2024filed 2 Feb 2024 | AKBA Akebia Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —454,950 at $0.00 | filing |
| 31 Jan 2024filed 2 Feb 2024 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Code A | —303,300 at $0.00 | filing |
| 2 Mar 2019filed 5 Mar 2019 | Amag Pharmaceuticals | SEC FORM 4 Code F | $14K982 at $14.76 | filing |
| 25 Feb 2019filed 27 Feb 2019 | Amag Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —25,000 | filing |
| 25 Feb 2019filed 27 Feb 2019 | Amag Pharmaceuticals | SEC FORM 4 Code A | —12,000 | filing |
| 25 Feb 2019filed 27 Feb 2019 | Amag Pharmaceuticals | SEC FORM 4 Code A | —12,000 | filing |
| 23 Feb 2019filed 26 Feb 2019 | Amag Pharmaceuticals | SEC FORM 4 Code F | $15K982 at $15.51 | filing |
| 4 Jan 2019filed 8 Jan 2019 | Amag Pharmaceuticals | SEC FORM 4 Code F | $58K3,555 at $16.19 | filing |
| 2 Mar 2018filed 6 Mar 2018 | Amag Pharmaceuticals | SEC FORM 4 Code A | —10,000 | filing |
News
Analyzing Akebia Therapeutics (NASDAQ:AKBA) and Pharming Group (NASDAQ:PHAR)AKBA · tickerreport.com · 18 Oct 2026Akebia Therapeutics to Conduct Investor Meetings at the Virtual U.S. Bancorp I BTIG Kidney Health ForumAKBA · manilatimes.net · 7 Oct 2026
0 headlines in the last 90 days name Nicholas Grund; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.